Treating benign prostatic hyperplasia with finasteride in Chinese men: One-year experience

Journal of the Formosan Medical Association

Volumn 95, Issue 8, 1996, Pages 650-652

  Chueh, Shih Chieh ^a   Yu, Hong Jeng ^a,b   Chiu, Tsu Yih ^b   Huang, Chao Yuan ^a   Lai, Ming Kuen ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

benign prostatic hyperplasia; finasteride; prostate specific antigen

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMPOTENCE; MALE; PROSTATE HYPERTROPHY;

AGED; AGED, 80 AND OVER; CHINA; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; STATISTICS, NONPARAMETRIC; TAIWAN; TUMOR MARKERS, BIOLOGICAL;

EID: 0029834709     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Berry SJ, Coffey DS, Walsh PC, et al: The development of human prostatic hyperplasia with age. J Urol 1984;132:474-9.
2. Lytton B, Emery JM, Havard BM: The incidence of benign prostatic obstruction. J Urol 1968;99:639-45.
3. Geller J: Benign prostatic hyperplasia: pathogenesis and medical therapy. J Am Geriatr Soc 1991;39:1208-16.
4. Peter DH, Sorkin EM: Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1953;46:177-208.
5. Steiner JF: Finasteride: a 5α-reductase inhibitor. Clin Pharm 1993;12:15-23.
6. The MK-906 (finasteride) study group: One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl 1991;12:372-5.
7. Gormley GJ, Stoner E, Bruskewitz RC, et al and the Finasteride study group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1184-91.
8. Mocellini AI, Gardiner R, Marshall V, et al: Finasteride in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-9.
9. Stoner E: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-94.
10. Geller J: Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol 1995;27:267-73.
11. Yu HJ, Chiu TY, Lai MK: Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled study. J Formos Med Assoc 1995;94:37-41.
12. Rifkin MD, Kurtz AB, Choi HY, et al: Endoscopic ultrasonic evaluation of the prostate using a transrectal probe: prospective evaluation and acoustic characterization. Radiology 1983;149:256-71.
13. Barry MJ, Fowler FJ, O'Leary MP, et al: The American Urological Association's symptom index for BPH. J Urol 1992;148:1549-57.
14. Guess HA: The prevalence of benign prostatic hyperplasia in population surveys. In: Garraway M, ed. Epidemiology of prostate disease. Berlin: Springer-Veralg; 1995, 121-32.
15. McConnell JD: The pathophysiology of benign prostatic hyperplasia. J Androl 1991;12:356-62.
16. Jenkins EP, Anderson S, Imperato-McGinley J, et al: Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest 1992;89:293-300.
17. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
18. Geller J. Effect of finasteride, a 5-alpha reductase inhibitor on prostate tissue androgens and prostate specific antigen. J Clin Endocrinol Metab 1990;71:1551-5.